New Century Financial Group LLC Purchases Shares of 76,035 The Chemours Company $CC

Key Points

• New Century Financial Group LLC has acquired 76,035 shares of The Chemours Company for approximately $871,000, representing a 0.05% ownership stake as of their latest SEC filing.
• Chemours reported a Q2 EPS of $0.58, exceeding analysts' expectations, with revenues of $1.62 billion, which is a 5.0% increase from the previous year.
• The company has cut its quarterly dividend to $0.0875 per share, reflecting a -12.50% dividend payout ratio and a dividend yield of 2.1%.

New Century Financial Group LLC purchased a new position in shares of The Chemours Company (NYSE:CC - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 76,035 shares of the specialty chemicals company's stock, valued at approximately $871,000. New Century Financial Group LLC owned 0.05% of Chemours as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. FNY Investment Advisers LLC acquired a new position in Chemours in the first quarter valued at $27,000. Farther Finance Advisors LLC grew its holdings in Chemours by 170.7% in the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock valued at $30,000 after buying an additional 1,444 shares during the period. UMB Bank n.a. increased its stake in shares of Chemours by 73.9% during the 1st quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock valued at $30,000 after acquiring an additional 948 shares during the last quarter. SouthState Corp purchased a new position in shares of Chemours during the 1st quarter worth about $34,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Chemours by 130.7% during the 2nd quarter. GAMMA Investing LLC now owns 3,175 shares of the specialty chemicals company's stock worth $36,000 after acquiring an additional 1,799 shares during the period. Institutional investors and hedge funds own 76.26% of the company's stock.

Chemours Stock Up 2.6%

Shares of NYSE:CC opened at $16.33 on Friday. The company has a market capitalization of $2.44 billion, a price-to-earnings ratio of -5.83 and a beta of 1.65. The company has a 50 day moving average of $14.94 and a two-hundred day moving average of $12.99. The Chemours Company has a 52-week low of $9.13 and a 52-week high of $22.38. The company has a quick ratio of 0.83, a current ratio of 1.68 and a debt-to-equity ratio of 17.16.

Chemours (NYSE:CC - Get Free Report) last posted its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 EPS for the quarter, topping analysts' consensus estimates of $0.46 by $0.12. The business had revenue of $1.62 billion for the quarter, compared to analysts' expectations of $1.57 billion. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The business's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.38 earnings per share. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts forecast that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 15th were paid a dividend of $0.0875 per share. The ex-dividend date was Friday, August 15th. This represents a $0.35 annualized dividend and a dividend yield of 2.1%. Chemours's dividend payout ratio (DPR) is currently -12.50%.

Insider Activity

In other Chemours news, CEO Denise Dignam purchased 4,068 shares of the business's stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average price of $12.06 per share, for a total transaction of $49,060.08. Following the completion of the purchase, the chief executive officer owned 191,546 shares in the company, valued at $2,310,044.76. The trade was a 2.17% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.47% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CC. Truist Financial lifted their price target on shares of Chemours from $18.00 to $21.00 and gave the company a "buy" rating in a report on Tuesday, September 16th. Royal Bank Of Canada lifted their price objective on Chemours from $14.00 to $15.00 and gave the company an "outperform" rating in a research note on Thursday, July 3rd. Mizuho boosted their target price on Chemours from $16.00 to $19.00 and gave the stock an "outperform" rating in a report on Tuesday, September 23rd. Finally, Zacks Research upgraded shares of Chemours from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 27th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $17.63.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.